Kadcyla

Trastuzumab emtansine, the active ingredient in Kadcyla, is an antibody‑drug conjugate presented as a 100 mg per vial (10 mg/mL) or 200 mg per vial (20 mg/mL) lyophilized powder for solution for infusion for intravenous use. It treats HER2‑positive metastatic breast cancer and HER2‑positive early breast cancer in the adjuvant setting.

GNH USA supplies Kadcyla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinical trial sites worldwide, ensuring quality and regulatory compliance. Our distribution network covers major regions across Europe, Asia and the Americas, facilitating reliable access to this targeted therapy.

Kadcyla is used in the management of HER2‑positive breast cancer, targeting the HER2 signaling pathway. - HER2‑positive metastatic breast cancer: improves progression‑free and overall survival in patients with advanced disease. - HER2‑positive early breast cancer (adjuvant setting): reduces the risk of disease recurrence after surgery and standard therapy. - HER2‑positive locally advanced breast cancer: provides disease control when surgery is not immediately feasible.

Kadcyla may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Nausea: sensation of needing to vomit, often mild. - Thrombocytopenia: reduced platelet count that may increase bleeding risk. - Elevated liver enzymes: increased ALT or AST indicating hepatic stress.

Serious or Rare Side Effects: - Cardiac toxicity: decrease in left ventricular ejection fraction or heart failure. - Interstitial lung disease: inflammation of lung tissue that can be life‑threatening. - Severe infusion reactions: anaphylaxis, hypotension, or bronchospasm during administration.

Before initiating Kadcyla therapy, several precautions should be observed to minimize risks. - Cardiac monitoring: perform baseline and periodic left ventricular ejection fraction assessments. - Liver function assessment: check transaminases before each treatment cycle. - Platelet count monitoring: evaluate for thrombocytopenia and adjust dosing if needed. - Hypersensitivity avoidance: do not administer to patients with known allergy to trastuzumab or DM1. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kadcyla can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Concomitant trastuzumab: increased risk of cardiac dysfunction. - Anthracycline chemotherapy: additive cardiotoxicity when given together. - Live vaccines: may reduce vaccine effectiveness and increase infection risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise DM1 exposure and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk due to thrombocytopenia. - Hormonal therapies (e.g., tamoxifen): potential additive hepatic effects. - CYP3A4 inducers (e.g., rifampin): may lower DM1 levels and reduce efficacy.